Limits...
Aberrant over-expression of TRPM7 ion channels in pancreatic cancer: required for cancer cell invasion and implicated in tumor growth and metastasis.

Yee NS, Kazi AA, Li Q, Yang Z, Berg A, Yee RK - Biol Open (2015)

Bottom Line: Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma significantly correlates with the size and stages of tumors.In human pancreatic adenocarcinoma cells in which TRPM7 is highly expressed, short hairpin RNA-mediated suppression of TRPM7 impairs cell invasion.The results demonstrate that TRPM7 channels are over-expressed in a proportion of the pre-malignant lesions and malignant tumors of the pancreas, and they are necessary for invasion by pancreatic cancer cells.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology-Oncology, Department of Medicine, Penn State College of Medicine, Program of Experimental Therapeutics, Penn State Hershey Cancer Institute, Penn State Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA nyee@hmc.psu.edu.

No MeSH data available.


Related in: MedlinePlus

ShRNA-mediated silencing of TRPM7 impaired invasion in pancreatic adenocarcinoma cells.(A) Non-transfected BxPC-3 cells assayed for invasion using the trans-well assay in the presence of 3% FBS or no FBS. (B,C) BxPC-3 cells transfected with non-targeting control (NC) shRNA or anti-TRPM7 shRNA analyzed for cell invasion in the presence of either 3% FBS (B) or 10% FBS (C). A representative image of the invaded cells stained with crystal violet is shown for each experimental group. Cell invasion is expressed as % control, and each column represents the mean ± standard error.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400593&req=5

f06: ShRNA-mediated silencing of TRPM7 impaired invasion in pancreatic adenocarcinoma cells.(A) Non-transfected BxPC-3 cells assayed for invasion using the trans-well assay in the presence of 3% FBS or no FBS. (B,C) BxPC-3 cells transfected with non-targeting control (NC) shRNA or anti-TRPM7 shRNA analyzed for cell invasion in the presence of either 3% FBS (B) or 10% FBS (C). A representative image of the invaded cells stained with crystal violet is shown for each experimental group. Cell invasion is expressed as % control, and each column represents the mean ± standard error.

Mentions: In the non-transfected BxPC-3 cells, cell invasion occurred in response to 3% FBS, while most of the cells failed to invade in the absence of serum (Fig. 6A). As compared to the control cells transfected with non-targeting shRNA, BxPC-3 cells with partially repressed TRPM7 had impaired ability to migrate and invade in response to either 3% or 10% FBS (Fig. 6B,C). Similarly, another pancreatic adenocarcinoma cell line (MIA PaCa-2) expressing anti-TRPM7 shRNA exhibited reduced ability of cell invasion (N.S.Y., personal observation). These results indicate that TRPM7 is required for invasion of the pancreatic cancer cells, and support a potential role of TRPM7 channels in tumor metastasis.


Aberrant over-expression of TRPM7 ion channels in pancreatic cancer: required for cancer cell invasion and implicated in tumor growth and metastasis.

Yee NS, Kazi AA, Li Q, Yang Z, Berg A, Yee RK - Biol Open (2015)

ShRNA-mediated silencing of TRPM7 impaired invasion in pancreatic adenocarcinoma cells.(A) Non-transfected BxPC-3 cells assayed for invasion using the trans-well assay in the presence of 3% FBS or no FBS. (B,C) BxPC-3 cells transfected with non-targeting control (NC) shRNA or anti-TRPM7 shRNA analyzed for cell invasion in the presence of either 3% FBS (B) or 10% FBS (C). A representative image of the invaded cells stained with crystal violet is shown for each experimental group. Cell invasion is expressed as % control, and each column represents the mean ± standard error.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400593&req=5

f06: ShRNA-mediated silencing of TRPM7 impaired invasion in pancreatic adenocarcinoma cells.(A) Non-transfected BxPC-3 cells assayed for invasion using the trans-well assay in the presence of 3% FBS or no FBS. (B,C) BxPC-3 cells transfected with non-targeting control (NC) shRNA or anti-TRPM7 shRNA analyzed for cell invasion in the presence of either 3% FBS (B) or 10% FBS (C). A representative image of the invaded cells stained with crystal violet is shown for each experimental group. Cell invasion is expressed as % control, and each column represents the mean ± standard error.
Mentions: In the non-transfected BxPC-3 cells, cell invasion occurred in response to 3% FBS, while most of the cells failed to invade in the absence of serum (Fig. 6A). As compared to the control cells transfected with non-targeting shRNA, BxPC-3 cells with partially repressed TRPM7 had impaired ability to migrate and invade in response to either 3% or 10% FBS (Fig. 6B,C). Similarly, another pancreatic adenocarcinoma cell line (MIA PaCa-2) expressing anti-TRPM7 shRNA exhibited reduced ability of cell invasion (N.S.Y., personal observation). These results indicate that TRPM7 is required for invasion of the pancreatic cancer cells, and support a potential role of TRPM7 channels in tumor metastasis.

Bottom Line: Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma significantly correlates with the size and stages of tumors.In human pancreatic adenocarcinoma cells in which TRPM7 is highly expressed, short hairpin RNA-mediated suppression of TRPM7 impairs cell invasion.The results demonstrate that TRPM7 channels are over-expressed in a proportion of the pre-malignant lesions and malignant tumors of the pancreas, and they are necessary for invasion by pancreatic cancer cells.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology-Oncology, Department of Medicine, Penn State College of Medicine, Program of Experimental Therapeutics, Penn State Hershey Cancer Institute, Penn State Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA nyee@hmc.psu.edu.

No MeSH data available.


Related in: MedlinePlus